PMID- 37048701
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230415
IS  - 2077-0383 (Print)
IS  - 2077-0383 (Electronic)
IS  - 2077-0383 (Linking)
VI  - 12
IP  - 7
DP  - 2023 Mar 30
TI  - Plasma Levels of Metalloproteinase 3 (MMP-3) and Metalloproteinase 7 (MMP-7) as 
      New Candidates for Tumor Biomarkers in Diagnostic of Breast Cancer Patients.
LID - 10.3390/jcm12072618 [doi]
LID - 2618
AB  - Matrix metalloproteinases (MMPs) are a group of enzymes that mediate both 
      physiological and pathological processes such as carcinogenesis. The role of 
      matrix metalloproteinase-3 (MMP-3) and (MMP-7) in the pathogenesis of breast 
      cancer (BC) has been demonstrated, suggesting that they may be considered as 
      potential markers of this condition. The aim of this study was to assess plasma 
      concentrations and diagnostic utility of MMP-3 and MMP-7 in 100 patients with 
      early-stage breast cancer with Luminal A subtype or Luminal B HER-negative 
      subtype, before and after surgical treatment, and in the following control 
      groups: patients with a benign tumor (fibroadenoma) and healthy subjects. The 
      concentrations of MMP-3 and MMP-7 were referenced to the levels of the widely 
      recognized marker for BC diagnosis CA 15-3. MMP-3 and MMP-7 was measured by ELISA 
      method and CA 15-3 by CMIA. Plasma levels of MMP-7 were significantly higher in 
      Luminal A and Luminal B HER2-negative subtype breast cancer patients as compared 
      to the healthy group. MMP-7 demonstrated comparable but mostly higher to CA 15-3 
      or MMP-3 values of diagnostic sensitivity, specificity, positive and negative 
      predictive values and AUC (0.6888 for Luminal A subtype; 0.7612 for Luminal B 
      HER2-negative; 0.7250 for BC total group, respectively) in the groups tested. The 
      combined use of the tested parameters resulted in a further increase in 
      diagnostic criteria and AUC. These results suggest the usefulness of combining 
      MMP-7 with CA 15-3 in the diagnostics of breast cancer, especially in Luminal B 
      HER2-negative subtypes patients, as a new candidate for tumor markers.
FAU - Lawicki, Pawel
AU  - Lawicki P
AUID- ORCID: 0000-0003-4377-085X
AD  - Department of Population Medicine and Lifestyle Diseases Prevention, Medical 
      University of Bialystok, 15-269 Bialystok, Poland.
FAU - Malinowski, Pawel
AU  - Malinowski P
AD  - Department of Oncological Surgery, Bialystok Oncology Center, 15-276 Bialystok, 
      Poland.
FAU - Motyka, Joanna
AU  - Motyka J
AUID- ORCID: 0000-0003-1815-2427
AD  - Department of Population Medicine and Lifestyle Diseases Prevention, Medical 
      University of Bialystok, 15-269 Bialystok, Poland.
FAU - Lawicki, Michal
AU  - Lawicki M
AD  - Department of Population Medicine and Lifestyle Diseases Prevention, Medical 
      University of Bialystok, 15-269 Bialystok, Poland.
FAU - Kicman, Aleksandra
AU  - Kicman A
AD  - Department of Aesthetic Medicine, Medical University of Bialystok, 15-267 
      Bialystok, Poland.
FAU - Kulesza, Monika
AU  - Kulesza M
AD  - Department of Population Medicine and Lifestyle Diseases Prevention, Medical 
      University of Bialystok, 15-269 Bialystok, Poland.
FAU - Gacuta, Ewa
AU  - Gacuta E
AD  - Department of Perinatology, University Clinical Hospital of Bialystok, 15-276 
      Bialystok, Poland.
FAU - Guszczyn, Tomasz
AU  - Guszczyn T
AD  - Department of Pediatric Orthopaedics and Traumatology, Medical University of 
      Bialystok, 15-089 Bialystok, Poland.
FAU - Januszkiewicz, Marcin
AU  - Januszkiewicz M
AD  - Department of Oncological Surgery, Bialystok Oncology Center, 15-276 Bialystok, 
      Poland.
FAU - Zbucka-Kretowska, Monika
AU  - Zbucka-Kretowska M
AD  - Department of Gynecological Endocrinology and Adolescent Gynecology, Medical 
      University of Bialystok, 15-276 Bialystok, Poland.
FAU - Lawicki, Slawomir
AU  - Lawicki S
AUID- ORCID: 0000-0001-6747-2123
AD  - Department of Population Medicine and Lifestyle Diseases Prevention, Medical 
      University of Bialystok, 15-269 Bialystok, Poland.
LA  - eng
PT  - Journal Article
DEP - 20230330
PL  - Switzerland
TA  - J Clin Med
JT  - Journal of clinical medicine
JID - 101606588
PMC - PMC10094779
OTO - NOTNLM
OT  - breast cancer
OT  - ca 15-3
OT  - fibroadenoma
OT  - luminal a subtype
OT  - luminal b her2-negative subtype
OT  - mmp-3
OT  - mmp-7
COIS- The authors declare no conflict of interest.
EDAT- 2023/04/14 06:00
MHDA- 2023/04/14 06:01
PMCR- 2023/03/30
CRDT- 2023/04/13 01:20
PHST- 2023/02/24 00:00 [received]
PHST- 2023/03/17 00:00 [revised]
PHST- 2023/03/28 00:00 [accepted]
PHST- 2023/04/14 06:01 [medline]
PHST- 2023/04/13 01:20 [entrez]
PHST- 2023/04/14 06:00 [pubmed]
PHST- 2023/03/30 00:00 [pmc-release]
AID - jcm12072618 [pii]
AID - jcm-12-02618 [pii]
AID - 10.3390/jcm12072618 [doi]
PST - epublish
SO  - J Clin Med. 2023 Mar 30;12(7):2618. doi: 10.3390/jcm12072618.